Log in Free sign up

Gracell Biotechnologies (GRCL) News and press releases

News

From Benzinga Pro

Gracell Biotechnologies: Q1 Earnings Insights

Gracell Biotechnologies (NASDAQ:GRCL) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Gracell Biotechnologies Q1 EPS $(0.07) Beats $(0.21) Estimate

Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.21) by 66.67 percent. This is a 72 percent increase over losses of $(0.25) per share

Earnings Scheduled For May 16, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Preview: Gracell Biotechnologies's Earnings

Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.21.

Gracell Biotech Offers Details Of Its Oral Abstract Presentation At American Society Of Clinical Oncology Meeting: Will Present On Jun. 5 at 10:35 a.m. EDT

Biotech, News, FDA, Events, General

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO,

Gracell Biotechnologies' Abstract On GC012F Accepted For Presentation At 2022 ASCO Annual Meeting

News, FDA, Events

Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

68 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation.

35 Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors.

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

12 Health Care Stocks Moving In Monday's Pre-Market Session

BTIG Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $18

News, Price Target, Initiation, Analyst Ratings

BTIG analyst Justin Zelin initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $18.

12 Health Care Stocks Moving In Thursday's Intraday Session

Intraday Update, Markets, Movers

96 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share.

12 Health Care Stocks Moving In Monday's Intraday Session

Intraday Update, Markets, Movers

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 671 companies achieved new lows for the year.

50 Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share.

Gracell Biotechnologies: Q4 Earnings Insights

Gracell Biotechnologies (NASDAQ:GRCL) reported its Q4 earnings results on Monday, March 14, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Gracell Biotechnologies Q4 EPS $(0.30) Beats $(0.33) Estimate

Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 60 percent increase over losses of $(0.75) per share

Press releases

From Benzinga Pro

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and

Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Earnings, Press Releases

Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at AACR 2022;

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company

Gracell Biotechnologies to Participate in Three Investor Conferences in May

News, Press Releases

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO,

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021

SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

Earnings, Health Care, Press Releases

Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human

Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference

News, Press Releases

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing

Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022

Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated